Andrew Hayes

Biography

Mr Hayes is a Consultant General Surgeon and Surgical Oncologist at the Sarcoma Unit and the Skin Unit at The Royal Marsden and Associate Honorary Faculty at the ICR. His pre-clinical training was at Oxford University and his clinical training was at St Bartholomew’s Hospital, London. He undertook his postgraduate surgical training in London. Mr Hayes spent three years of research training at the Lombardi Cancer Center, Georgetown University Hospital, Washington DC, US, for which he was awarded a PhD in 2001. In 2002, Mr Hayes was awarded a Hunterian Professorship by the Royal College of Surgeons in England for his research into angiogenesis as a therapeutic approach for cancer. For the last 14 years, Mr Hayes has developed a specialist surgical practice in soft-tissue sarcoma and advanced melanoma. He leads the Isolated Limb Perfusion programme, which provides a national service for regional chemotherapy for patients with advanced limb malignancy. He is currently the Lead Clinician of The Royal Marsden’s Skin Unit as well as Clinical Director of the Rare Cancers Clinical Business Unit, and Co-Chair of the London and South East England Sarcoma Advisory Group. Mr Hayes has published widely on clinical aspects of sarcoma and melanoma, culminating most recently in publication of the long-term results of a multinational randomised trial of surgical margins in primary melanoma. For the last eight years, Mr Hayes has also been running a translational research programme in the ICR developing new therapeutic agents to be delivered alongside standard chemotherapy by isolated limb perfusion for the treatment of advanced irresectable limb malignancies.

Research Interest

The Sarcoma and Melanoma Surgery Team consists of surgical oncologists who undertake both translational and clinical research in soft tissue sarcoma, melanoma and other rare tumours of the soft tissues. Within the laboratory, our research focus is on developing new treatments for advanced limb malignancies treated by the technique of isolated limb perfusion that delivers regional chemotherapy to the affected limb. Specifically, Mr Henry Smith is investigating the combination of oncolytic viral therapy and immunotherapy with traditional chemotherapeutic drugs to improve both the local control of tumours and to prevent or treat metastatic disease. The clinical research interests within our team include retroperitoneal sarcoma surgery. Mr Dirk Strauss is the UK Principal investigator for the EORTC International STRASS Randomised trial, which is investigating the role of pre-operative radiotherapy in improving survival for retroperitoneal sarcoma and has published extensively on clinical and oncological outcomes after retroperitoneal sarcoma surgery.